2024
ACR Appropriateness Criteria® Female Breast Cancer Screening: 2023 Update
Imaging P, Niell B, Jochelson M, Amir T, Brown A, Adamson M, Baron P, Bennett D, Chetlen A, Dayaratna S, Freer P, Ivansco L, Klein K, Malak S, Mehta T, Moy L, Neal C, Newell M, Richman I, Schonberg M, Small W, Ulaner G, Slanetz P. ACR Appropriateness Criteria® Female Breast Cancer Screening: 2023 Update. Journal Of The American College Of Radiology 2024, 21: s126-s143. PMID: 38823941, DOI: 10.1016/j.jacr.2024.02.019.Peer-Reviewed Original ResearchConceptsReduce breast cancer mortalityRecommendation of mammographyBreast cancerBreast cancer mortalityBreast cancer riskBreast cancer screeningDigital breast tomosynthesisEvidence-based guidelinesAmerican College of Radiology Appropriateness CriteriaPeer-reviewed journalsMultidisciplinary expert panelRAND/UCLA Appropriateness Method User ManualMultiple different imaging modalitiesPeer-reviewed literatureScreening recommendationsCancer screeningCancer mortalityCancer riskGuideline developmentAppropriateness of imagingRecommendations AssessmentBreast tomosynthesisEstablished methodology principlesExpert panelAmerican CollegeEstimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States.
Richman I, Gross C. Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States. Annals Of Internal Medicine 2024, 177: 403-404. PMID: 38498894, DOI: 10.7326/l23-0485.Peer-Reviewed Original Research
2023
Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States.
Richman I, Long J, Soulos P, Wang S, Gross C. Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States. Annals Of Internal Medicine 2023, 176: 1172-1180. PMID: 37549389, PMCID: PMC10623662, DOI: 10.7326/m23-0133.Peer-Reviewed Original ResearchConceptsCumulative incidenceBreast cancerBreast cancer screeningUnscreened womenOlder womenCancer screeningBreast cancer-specific deathBreast cancer overdiagnosisService Medicare claimsRetrospective cohort studyCancer-specific deathBreast cancer deathsWomen 70 yearsHarms of overdiagnosisNational Cancer InstituteBreast cancer diagnosisCohort studyCancer overdiagnosisCancer deathSEER programMedicare claimsCancer InstituteOverdiagnosisGreater incidenceCancerEliminating Financial Barriers to Breast Cancer Screening—When Free Is Not Really Free
Richman I, Fendrick A. Eliminating Financial Barriers to Breast Cancer Screening—When Free Is Not Really Free. JAMA Network Open 2023, 6: e234898. PMID: 36972055, DOI: 10.1001/jamanetworkopen.2023.4898.Commentaries, Editorials and Letters
2022
Artificial Intelligence in Breast Cancer Screening
Potnis K, Ross J, Aneja S, Gross C, Richman I. Artificial Intelligence in Breast Cancer Screening. JAMA Internal Medicine 2022, 182: 1306-1312. PMID: 36342705, PMCID: PMC10623674, DOI: 10.1001/jamainternmed.2022.4969.Peer-Reviewed Original ResearchBreast cancer screening during the COVID-19 pandemic: moving from disparities to health equity
Richman I, Tessier-Sherman B, Galusha D, Oladele CR, Wang K. Breast cancer screening during the COVID-19 pandemic: moving from disparities to health equity. Journal Of The National Cancer Institute 2022, 115: 139-145. PMID: 36069622, PMCID: PMC9494402, DOI: 10.1093/jnci/djac172.Peer-Reviewed Original ResearchConceptsBreast cancer screeningCancer screeningHealth systemHealth equityBreast cancer controlRoutine health careCOVID-19 pandemicCOVID-19 waveMammography ratesCancer controlMammography useMultifactorial conditionHealth disparitiesWhite womenScreening mammographyHealth careWomenCOVID-19Subsequent COVID-19 wavesLower ratesNumber of studiesMammographyDisparitiesPandemicSpecific patternsInsurance Coverage Mandates and the Adoption of Digital Breast Tomosynthesis
Richman IB, Long JB, Kyanko KA, Xu X, Gross CP, Busch SH. Insurance Coverage Mandates and the Adoption of Digital Breast Tomosynthesis. JAMA Network Open 2022, 5: e224208. PMID: 35333358, PMCID: PMC8956980, DOI: 10.1001/jamanetworkopen.2022.4208.Peer-Reviewed Original ResearchConceptsCoverage mandateCohort studyBreast cancerPocket paymentsDigital breast tomosynthesisInsurance coveragePoints 2 yearsAffordable Care ActMAIN OUTCOMEScreening mammogramsStudy periodDirect costsBreast tomosynthesisPatient ProtectionCare ActWomenCancerAssociationYearsPrivate insurersPatientsCost sharing
2021
Trends in Breast Cancer Screening Costs Among Privately Insured Women Aged 40 to 64 Years
Richman IB, Long JB, Kunst N, Kyanko K, Xu X, Busch S, Gross CP. Trends in Breast Cancer Screening Costs Among Privately Insured Women Aged 40 to 64 Years. JAMA Internal Medicine 2021, 181: 1665-1668. PMID: 34459853, PMCID: PMC8406208, DOI: 10.1001/jamainternmed.2021.4832.Peer-Reviewed Original ResearchComparative Effectiveness of Digital Breast Tomosynthesis and Mammography in Older Women
Upneja A, Long JB, Aminawung JA, Kyanko KA, Kunst N, Xu X, Busch SH, Gross CP, Richman IB. Comparative Effectiveness of Digital Breast Tomosynthesis and Mammography in Older Women. Journal Of General Internal Medicine 2021, 37: 1870-1876. PMID: 34595682, PMCID: PMC8483166, DOI: 10.1007/s11606-021-07132-6.Peer-Reviewed Original ResearchConceptsWomen 75Older womenBreast cancerAdditional cancersSubsequent imagingWomen 67Stage ITime of diagnosisEarly-stage cancerHigh rateCancer detectionConclusionsBreast cancerPrior cancerPotential confoundersScreening outcomesHealth outcomesService beneficiariesComparative effectivenessScreening mammogramsAge groupsCancerLogistic regressionResultsOur studyWomenBreast tomosynthesisComparative Effectiveness of Digital Breast Tomosynthesis for Breast Cancer Screening Among Women 40-64 Years Old
Richman IB, Long JB, Hoag JR, Upneja A, Hooley R, Xu X, Kunst N, Aminawung JA, Kyanko KA, Busch SH, Gross CP. Comparative Effectiveness of Digital Breast Tomosynthesis for Breast Cancer Screening Among Women 40-64 Years Old. Journal Of The National Cancer Institute 2021, 113: 1515-1522. PMID: 33822120, PMCID: PMC8757313, DOI: 10.1093/jnci/djab063.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiopsyBreastBreast NeoplasmsEarly Detection of CancerFemaleHumansMammographyMass ScreeningMiddle AgedConceptsHigher cancer detection rateCancer detection rateBreast cancer screeningCancer screeningScreening outcomesBreast cancer screening outcomesDigital breast tomosynthesisCancer screening outcomesPopulation-level adoptionReal-world cohortMultivariable logistic regressionHigher biopsy ratesPatient-level analysisPopulation health impactDetection rateIncident cancerClinical outcomesWomen 40Biopsy rateObservational studyComparative effectivenessLogistic regressionYoung womenPrivate health insurersWomenUnderstanding Regional Variation in the Cost of Breast Cancer Screening Among Privately Insured Women in the United States
Kunst N, Long JB, Xu X, Busch SH, Kyanko KA, Lindau ST, Richman IB, Gross CP. Understanding Regional Variation in the Cost of Breast Cancer Screening Among Privately Insured Women in the United States. Medical Care 2021, 59: 437-443. PMID: 33560712, PMCID: PMC8611614, DOI: 10.1097/mlr.0000000000001506.Peer-Reviewed Original Research
2020
Breast cancer supplemental screening: Women’s knowledge and utilization in the era of dense breast legislation
Aminawung JA, Hoag JR, Kyanko KA, Xu X, Richman IB, Busch SH, Gross CP. Breast cancer supplemental screening: Women’s knowledge and utilization in the era of dense breast legislation. Cancer Medicine 2020, 9: 5662-5671. PMID: 32537899, PMCID: PMC7402830, DOI: 10.1002/cam4.3218.Peer-Reviewed Original ResearchIndustry Payments and New Breast Cancer Screening Technology Use
Potnis KC, Gross CP, Richman IB. Industry Payments and New Breast Cancer Screening Technology Use. Journal Of General Internal Medicine 2020, 36: 1440-1442. PMID: 32468434, PMCID: PMC8131452, DOI: 10.1007/s11606-020-05771-9.Peer-Reviewed Original ResearchUse and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance
Kunst N, Long JB, Xu X, Busch SH, Kyanko KA, Richman IB, Gross CP. Use and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance. JAMA Internal Medicine 2020, 180: 799-801. PMID: 32202606, PMCID: PMC7147248, DOI: 10.1001/jamainternmed.2020.0262.Peer-Reviewed Original ResearchDense Breast Notification Laws, Education, and Women’s Awareness and Knowledge of Breast Density: a Nationally Representative Survey
Kyanko KA, Hoag J, Busch SH, Aminawung JA, Xu X, Richman IB, Gross CP. Dense Breast Notification Laws, Education, and Women’s Awareness and Knowledge of Breast Density: a Nationally Representative Survey. Journal Of General Internal Medicine 2020, 35: 1940-1945. PMID: 31916210, PMCID: PMC7351910, DOI: 10.1007/s11606-019-05590-7.Peer-Reviewed Original Research
2019
Association of State Dense Breast Notification Laws With Supplemental Testing and Cancer Detection After Screening Mammography.
Busch SH, Hoag JR, Aminawung JA, Xu X, Richman IB, Soulos PR, Kyanko KA, Gross CP. Association of State Dense Breast Notification Laws With Supplemental Testing and Cancer Detection After Screening Mammography. American Journal Of Public Health 2019, 109: 762-767. PMID: 30896987, PMCID: PMC6459654, DOI: 10.2105/ajph.2019.304967.Peer-Reviewed Original ResearchMeSH KeywordsAdultBreast DensityBreast NeoplasmsEarly Detection of CancerFemaleHumansMammographyMass ScreeningMiddle AgedConceptsSupplemental screeningCancer detectionMore breast cancersMagnetic resonance imagingPossible benefitsBreast cancerSupplemental ultrasoundBreast biopsySupplemental testingResonance imagingUse of ultrasoundLogistic regressionScreening mammographyCancer diagnosisUltrasoundSignificant differencesSupplemental testsMore ultrasoundMammographyUS statesBreast cancer detectionMammogramsAssociationScreeningBiopsyNew Breast Cancer Screening Technologies in Older Women—Is It Time to Pump the Brakes?
Richman IB, Gross CP. New Breast Cancer Screening Technologies in Older Women—Is It Time to Pump the Brakes? JAMA Internal Medicine 2019, 179: 289-290. PMID: 30640376, DOI: 10.1001/jamainternmed.2018.7767.Commentaries, Editorials and Letters
2018
Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP. Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. Journal Of Clinical Oncology 2018, 36: 1619-1627. PMID: 29659329, PMCID: PMC5978470, DOI: 10.1200/jco.2017.76.5941.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCost-Benefit AnalysisFemaleGene Expression ProfilingHumansNeoplasm StagingConceptsCost-effectiveness analysisChemotherapy useBreast cancerEarly-stage breast cancerStudy designIncremental cost-effectiveness ratioODX recurrence scoreHigh-risk patientsLow-risk patientsRisk of biasCost-effectiveness ratioCost-effectiveness estimatesIndustry fundingDistant recurrenceIndustry-funded studiesClinical characteristicsTumor characteristicsRecurrence scoreChemotherapy decisionsScore groupClinical practiceSystematic reviewODXPatientsCancer
2016
Breast Density Notification Legislation and Breast Cancer Stage at Diagnosis: Early Evidence from the SEER Registry
Richman I, Asch SM, Bendavid E, Bhattacharya J, Owens DK. Breast Density Notification Legislation and Breast Cancer Stage at Diagnosis: Early Evidence from the SEER Registry. Journal Of General Internal Medicine 2016, 32: 603-609. PMID: 27844260, PMCID: PMC5442000, DOI: 10.1007/s11606-016-3904-y.Peer-Reviewed Original ResearchConceptsBreast density notification legislationProportion of womenBreast cancer stageCancer stageBreast cancerMetastatic diseaseEnd Results (SEER) Program registryTime of diagnosisInvasive breast cancerBreast density notification lawsSEER registryControl stateDuctal carcinomaInvasive cancerProgram registryAge 40Potential confoundingLimited followSignificant associationIntervention statesDense breastsResultsOur studyCancerDiagnosisEarly detection